ICON Portfolio of AI Tools Drives Clinical Trial Efficiencies
ICON plc (NASDAQ: ICLR) announced the expansion of its artificial intelligence (AI) tools portfolio to enhance clinical trial processes. The company has established an AI Centre of Excellence, supported by an AI Governance Committee, to develop and deploy AI solutions.
The new solutions include: iSubmit for automated document management, Mapi Research Trust COA for clinical outcome assessments, FORWARD+ for resource management, Study Start-up Site Contracts for contract drafting, and OMR AI Navigation Assistant for operational metrics analysis.
ICON received an Enterprise Ireland grant to further enhance its AI capabilities. A recent company survey revealed that 13% of biopharma companies face challenges in systematically incorporating AI technologies despite their heavy use in single development programs.
ICON plc (NASDAQ: ICLR) ha annunciato l'espansione del suo portafoglio di strumenti di intelligenza artificiale (IA) per migliorare i processi degli studi clinici. L'azienda ha istituito un Centro di Eccellenza per l'IA, supportato da un Comitato di Governance dell'IA, per sviluppare e mettere in esercizio soluzioni IA.
Le nuove soluzioni includono: iSubmit per la gestione automatizzata dei documenti, Mapi Research Trust COA per le valutazioni degli esiti clinici, FORWARD+ per la gestione delle risorse, Study Start-up Site Contracts per la redazione di contratti, e OMR AI Navigation Assistant per l'analisi delle metriche operative.
ICON ha ricevuto un finanziamento da Enterprise Ireland per migliorare ulteriormente le sue capacità di IA. Un recente sondaggio aziendale ha rivelato che il 13% delle aziende biopharma affronta sfide nell'integrare sistematicamente le tecnologie IA nonostante il loro ampio utilizzo in singoli programmi di sviluppo.
ICON plc (NASDAQ: ICLR) anunció la expansión de su cartera de herramientas de inteligencia artificial (IA) para mejorar los procesos de ensayos clínicos. La empresa ha establecido un Centro de Excelencia en IA, respaldado por un Comité de Gobernanza de IA, para desarrollar e implementar soluciones de IA.
Las nuevas soluciones incluyen: iSubmit para la gestión automatizada de documentos, Mapi Research Trust COA para las evaluaciones de resultados clínicos, FORWARD+ para la gestión de recursos, Study Start-up Site Contracts para la redacción de contratos, y OMR AI Navigation Assistant para el análisis de métricas operativas.
ICON recibió una subvención de Enterprise Ireland para mejorar aún más sus capacidades de IA. Una encuesta reciente de la empresa reveló que el 13% de las empresas biofarmacéuticas enfrenta desafíos para incorporar sistemáticamente las tecnologías de IA a pesar de su uso intensivo en programas de desarrollo individuales.
ICON plc (NASDAQ: ICLR)는 임상 시험 프로세스를 개선하기 위해 인공지능(AI) 도구 포트폴리오를 확장했다고 발표했습니다. 이 회사는 AI 솔루션을 개발하고 배포하기 위해 AI 거버넌스 위원회의 지원을 받는 AI 우수 센터를 설립했습니다.
새로운 솔루션에는: iSubmit 문서 관리 자동화, Mapi Research Trust COA 임상 결과 평가, FORWARD+ 자원 관리, Study Start-up Site Contracts 계약 초안 작성, OMR AI Navigation Assistant 운영 메트릭스 분석이 포함됩니다.
ICON은 AI 역량을 더욱 향상하기 위해 Enterprise Ireland의 지원금을 받았습니다. 최근 회사 조사에 따르면 바이오 제약 회사의 13%가 단일 개발 프로그램에서 AI 기술을 광범위하게 사용함에도 불구하고 시스템적으로 통합하는 데 어려움을 겪고 있다는 사실이 밝혀졌습니다.
ICON plc (NASDAQ: ICLR) a annoncé l'élargissement de son portefeuille d'outils d'intelligence artificielle (IA) pour améliorer les processus des essais cliniques. L'entreprise a établi un Centre d'Excellence de l'IA, soutenu par un Comité de Gouvernance de l'IA, afin de développer et déployer des solutions IA.
Les nouvelles solutions comprennent : iSubmit pour la gestion automatisée des documents, Mapi Research Trust COA pour les évaluations des résultats cliniques, FORWARD+ pour la gestion des ressources, Study Start-up Site Contracts pour la rédaction des contrats, et OMR AI Navigation Assistant pour l'analyse des mesures opérationnelles.
ICON a reçu une subvention d'Enterprise Ireland pour renforcer encore ses capacités en IA. Une enquête récente au sein de l'entreprise a révélé que 13% des sociétés biopharmaceutiques rencontrent des difficultés à intégrer systématiquement les technologies d'IA malgré leur utilisation intensive dans des programmes de développement individuels.
ICON plc (NASDAQ: ICLR) gab die Erweiterung seines Portfolios an Werkzeugen für künstliche Intelligenz (KI) bekannt, um die Abläufe in klinischen Studien zu verbessern. Das Unternehmen hat ein KI-Exzellenzzentrum eingerichtet, das von einem KI-Governance-Ausschuss unterstützt wird, um KI-Lösungen zu entwickeln und einzusetzen.
Zu den neuen Lösungen gehören: iSubmit für das automatisierte Dokumentenmanagement, Mapi Research Trust COA für klinische Ergebnisbewertungen, FORWARD+ für das Ressourcenmanagement, Study Start-up Site Contracts für die Vertragserstellung und OMR AI Navigation Assistant für die Analyse operativer Kennzahlen.
ICON erhielt einen Zuschuss von Enterprise Ireland, um seine KI-Fähigkeiten weiter zu verbessern. Eine kürzlich durchgeführte Unternehmensumfrage ergab, dass 13% der Biopharma-Unternehmen Schwierigkeiten haben, KI-Technologien systematisch zu integrieren, obwohl diese in einzelnen Entwicklungsprogrammen intensiv genutzt werden.
- Received Enterprise Ireland grant for AI development
- Launched five new AI tools for clinical trial optimization
- Established dedicated AI Centre of Excellence
- Survey shows only 13% of biopharma companies heavily use AI in development programs
- Industry facing challenges in systematic AI implementation
Insights
This strategic expansion of ICON's AI portfolio represents a significant competitive advancement in the $50+ billion CRO market. The introduction of five specialized AI tools addresses critical pain points in clinical trial management that traditionally consume substantial time and resources:
The new AI suite targets key operational bottlenecks:
- iSubmit tackles document management automation, historically a major cost center in clinical trials
- FORWARD+ addresses resource allocation efficiency, important for managing the estimated $2-3 million average cost per trial site
- Study Start-up Site Contracts could significantly reduce the typical 6-8 week contract negotiation period
Enterprise Ireland's backing provides both financial support and validation of ICON's AI strategy. The dedicated AI Centre of Excellence, supported by an AI Governance Committee, establishes a robust framework for sustainable innovation while addressing critical compliance and ethical considerations.
The low 13% adoption rate of AI in biopharma companies presents a substantial market opportunity. As the industry faces increasing pressure to reduce the typical $1-2 billion drug development costs, ICON's comprehensive AI solution suite positions it favorably to capture market share from competitors still developing similar capabilities.
The integration with existing award-winning tools like One Search, ICONex and Cassandra creates a comprehensive ecosystem that could significantly differentiate ICON in the market. This holistic approach to AI implementation addresses the systematic incorporation challenges cited by biopharma companies, potentially accelerating industry-wide adoption.
Enterprise
ICON has invested significantly in its AI and digital capabilities through the establishment of its AI Centre of Excellence. The centre, which comprises a dedicated team of data scientists, engineers and domain experts, is responsible for developing and deploying AI solutions that accelerate trials, enhance data and optimise operational efficiencies. The centre is supported by an AI Governance Committee, which oversees ethical, legal and data privacy standards in the deployment of new solutions.
The latest solutions to be launched are:
- iSubmit, which automates the clinical trial document management process. It uses AI to improve compliance, reduce the burden on clinical project teams, and manage documents in an efficient and accurate way based on defined rules.
- Mapi Research Trust COA leverages AI to remain current with latest Clinical Outcome Assessments (COAs) from public sources in near real-time. It provides comprehensive intelligence to support optimal clinical trial protocols/designs.
- FORWARD+ is an AI-enabled capability that provides industry-leading visibility into resource demands, allocations and forecasting. FORWARD+ ensures efficient resource management through the clinical trial process.
- Study Start-up Site Contracts is an AI-enabled capability that streamlines the clinical contract drafting process by leveraging historical clinical contracts in order to create comprehensive near final draft contracts.
- OMR AI Navigation Assistant empowers operational clinical study metrics with generative AI to provide industry-leading analytics to transform data into business insights.
Based on its success to date in implementing innovative AI solutions for its customers, ICON plans to further enhance its award-winning capabilities in how AI can drive productivity and efficiencies in clinical trials, with support from Enterprise Ireland.
This sustained focus on investment in AI solutions by ICON will support its customers as they look to overcome some of the challenges in realising the potential of AI in drug development. A recent ICON survey of biopharma companies found that
Tom O’Leary, CIO at ICON, commented: “Our research indicates that while the potential of AI to transform the drug development process is widely acknowledged, realising this potential at scale will take time and investment. As a leading clinical research organisation, it is our role to innovate the clinical trial process to support our customers in delivering new medicines to patients faster. We’re pleased to launch these additional new solutions, developed in a responsible and comprehensive way, which will deliver faster, smarter and more reliable outcomes for our customers.”
Leo Clancy, CEO, Enterprise Ireland, commented: “Enterprise Ireland is delighted to support ICON in advancing its AI capabilities, which are driving significant innovation in the clinical trial process. By investing in cutting-edge technologies, ICON is not only enhancing efficiency and compliance but also accelerating the development of life-saving treatments. This partnership exemplifies how Irish companies are leading the way in leveraging AI to address global challenges in healthcare and deliver meaningful impact for patients worldwide.”
ICON’s latest AI solutions complement its existing multi-award-winning AI tools. These include One Search, which enables access to multiple data sources and provides the visualisation and tools necessary for optimum site identification, based on ICON and industry data of site capability, experience and performance. ICONex maps out global networks of key opinion leaders across therapeutic areas, reducing the time it takes to identify the most influential experts for clinical trials from weeks to minutes. Cassandra predicts post-marketing study requirements early, allowing for proactive planning and reducing the risk of regulatory delays.
For further information please visit: www.iconplc.com/ai.
About ICON plc
ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in
ICON/ICLR-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20250130558178/en/
Media contacts:
Claire Quinn, Corporate Communications, ICON
+353 87 4066091
claire.quinn@iconplc.com
Lisa Henry, Weber Shandwick (PR adviser)
+44 7785 458203
lhenry@webershandwick.com
Source: ICON plc
FAQ
What new AI tools did ICON (ICLR) launch in 2024?
How is Enterprise Ireland supporting ICON's (ICLR) AI development?
What percentage of biopharma companies heavily use AI according to ICON's (ICLR) survey?
What is ICON's (ICLR) AI Centre of Excellence?
